Bibliography
- Mancia G, De Backer G, Dominiczak A, Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
- Egan BM, Zhao Y, Axon RN, Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-58
- Calhoun DA, Jones D, Textor S, American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-26
- Seravalle G, Volpe M, Ganz F, Sympathetic nerve traffic, insulin resistance and baroreflex control of circulation in patients with resistant hypertension [abstract]. Eur Heart J 2011;32:S500
- Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30
- Engbaek M, Hjerrild M, Hallas J, The effcts of low dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010;4:290-4
- de Souza F, Muxfeldt E Fiszman R, Salles G. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Hypertension 2010;55:147-52
- Grassi G, Mancia G. New therapeutic approaches for resistant hypertension. J Nephrol 2012;25:276-81
- Vaclavik J, Sedlak R, Plachy M, Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-75
- Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of white-coat and resistant hypertension. Nat Rev Cardiol 2011;8:686-93
- Grassi G, Seravalle G, Dell'Oro R, Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000;36:538-42
- Jordan J, Yumuk V, Schlaich M, Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012;30:1047-55
- van den Meiracker AH, Baggen RG, Pauli S, Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-92
- Mehdi UF, Adams-Huet B, Raskin P, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20:2641-50